137 related articles for article (PubMed ID: 30334452)
1. SLC27A2 regulates miR-411 to affect chemo-resistance in ovarian cancer.
Chen FD; Chen HH; Ke SC; Zheng LR; Zheng XY
Neoplasma; 2018 Nov; 65(6):915-924. PubMed ID: 30334452
[TBL] [Abstract][Full Text] [Related]
2. Reduced SLC27A2 induces cisplatin resistance in lung cancer stem cells by negatively regulating Bmi1-ABCG2 signaling.
Su J; Wu S; Tang W; Qian H; Zhou H; Guo T
Mol Carcinog; 2016 Nov; 55(11):1822-1832. PubMed ID: 26513225
[TBL] [Abstract][Full Text] [Related]
3. Upregulated miR-132 in Lgr5
Zhang L; Guo X; Zhang D; Fan Y; Qin L; Dong S; Zhang L
Mol Carcinog; 2017 Sep; 56(9):2022-2034. PubMed ID: 28383763
[TBL] [Abstract][Full Text] [Related]
4. miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.
Sun J; Cai X; Yung MM; Zhou W; Li J; Zhang Y; Li Z; Liu SS; Cheung ANY; Ngan HYS; Li Y; Dai Z; Kai Y; Tzatsos A; Peng W; Chan DW; Zhu W
Oncogene; 2019 Jan; 38(4):564-580. PubMed ID: 30166592
[TBL] [Abstract][Full Text] [Related]
5. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
[TBL] [Abstract][Full Text] [Related]
6. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
[TBL] [Abstract][Full Text] [Related]
7. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.
Xu S; Fu GB; Tao Z; OuYang J; Kong F; Jiang BH; Wan X; Chen K
Oncotarget; 2015 Sep; 6(28):26457-71. PubMed ID: 26238185
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
9. Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential.
Zhao L; Ren Y; Tang H; Wang W; He Q; Sun J; Zhou X; Wang A
Oncotarget; 2015 Dec; 6(42):44538-50. PubMed ID: 26517090
[TBL] [Abstract][Full Text] [Related]
10. Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells.
Samuel P; Pink RC; Caley DP; Currie JM; Brooks SA; Carter DR
Tumour Biol; 2016 Feb; 37(2):2565-73. PubMed ID: 26386726
[TBL] [Abstract][Full Text] [Related]
11. MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
Xiao F; Li Y; Wan Y; Xue M
Cancer Chemother Pharmacol; 2018 May; 81(5):935-947. PubMed ID: 29594361
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells.
Cheng W; Liu T; Wan X; Gao Y; Wang H
FEBS J; 2012 Jun; 279(11):2047-59. PubMed ID: 22498306
[TBL] [Abstract][Full Text] [Related]
13. Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
Xu J; Wu J; Fu C; Teng F; Liu S; Dai C; Shen R; Jia X
J Cell Physiol; 2018 Jun; 233(6):5034-5043. PubMed ID: 29219179
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
Zhang X; Huang L; Zhao Y; Tan W
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
[TBL] [Abstract][Full Text] [Related]
15. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
Zhang Y; Huang S; Guo Y; Li L
Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
[TBL] [Abstract][Full Text] [Related]
16. MiR-514 attenuates proliferation and increases chemoresistance by targeting ATP binding cassette subfamily in ovarian cancer.
Xiao S; Zhang M; Liu C; Wang D
Mol Genet Genomics; 2018 Oct; 293(5):1159-1167. PubMed ID: 29752546
[TBL] [Abstract][Full Text] [Related]
17. Deregulation of miR-128 in ovarian cancer promotes cisplatin resistance.
Li B; Chen H; Wu N; Zhang WJ; Shang LX
Int J Gynecol Cancer; 2014 Oct; 24(8):1381-8. PubMed ID: 25248111
[TBL] [Abstract][Full Text] [Related]
18. STAT3 regulated
Jin P; Liu Y; Wang R
Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 30061175
[TBL] [Abstract][Full Text] [Related]
19. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
20. miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway.
van Jaarsveld MT; van Kuijk PF; Boersma AW; Helleman J; van IJcken WF; Mathijssen RH; Pothof J; Berns EM; Verweij J; Wiemer EA
Mol Cancer; 2015 Nov; 14():196. PubMed ID: 26576679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]